President Donald Trump Was Right... Again

A new study shows that hydroxychloroquine (HCQ), the antimalarial drug, combined with azithromycin (AZM), could increase the rate of survival by nearly three times for severely ill COVID-19 patients. The observation study analyzed 255 mechanically ventilated patients at the Saint Barnabas Medical Center in New Jersey.

“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the study, published by medRxiv. says in its conclusion.

By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot.